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Objectives: an increased intima media thickness (IMT) is an early indicator of the atherosclerotic process. We investigated
the early effect of atorvastatin on the common carotid artery (CCA) and common femoral artery (CFA) IMT.
Methods: the IMT was measured in the CCA and the CFA of hyperlipidaemic patients referred with peripheral vascular
disease. The measurements were performed using an automated radio frequency IMT technique pre-treatment and at 4
and 8 weeks post-treatment with 20 mg/day atorvastatin.
Results: patients (14 men; 11 women), median age 69 years (range: 48–81) had a CCA-IMT mean (SD) of 0.79 (0.21) mm
pre-treatment, 0.75 (0.22) mm after 4 weeks, and 0.64 (0.15) mm after 8 weeks. The ANOVA test was significant (p=
0.024) for the CCA-IMT trend. The corresponding CFA-IMT readings were 0.83 (0.13) mm, 0.80 (0.09) mm and
0.69 (0.14) mm (p=0.0003). After 8 weeks of treatment there was a significant reduction in total cholesterol 6.0 (0.3) to
4.3 (0.8) mmol/l, p=0.0004 and low-density lipoprotein cholesterol 3.7 (0.2) to 2.2 (0.5), p=0.0001. There was a significant
decrease in median serum creatinine levels after 8 weeks treatment: 87 mol/l (range 67–114) to 84 mol/l (range: 64–112),
p=0.007.
Conclusions: cholesterol-lowering with atorvastatin 20 mg/day leads to a decrease in CCA-IMT and CFA-IMT. This
difference achieved significance after 8 weeks of treatment, but a trend was visible at 4 weeks. These rapid changes in
IMT may be attributable to an anti-inflammatory effect. IMT measurement may be a useful tool to rapidly assess the
effect of drug treatment on the atherosclerotic process.
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Introduction arteries.12 There are only a few studies involving the
common femoral artery IMT (CFA-IMT). They showed
that the combined assessment of the carotid and fem-The common carotid artery intima media thickness
oral arterial walls provides a more accurate estimate(IMT) (CCA-IMT) can be measured accurately non-
of the atherosclerotic burden in patients with familialinvasively.1–5 Furthermore, an increased CCA-IMT is
hyperlipidaemia.13 The femoral and carotid IMT wasassociated with major cardiovascular risk factors and
also increased in smokers without other vascular riskis a powerful predictor of cardiovascular events, par-
factors.14,15 B-mode (two-dimensional) duplex ultra-ticularly those associated with ischaemic heart disease
sound is also increasingly used for non-invasive visu-(IHD).6–9 In 133 patients the severity of coronary dis-
alisation and monitoring of atherosclerotic changes inease, as shown by coronary angiography, was sig-
the vasculature. Its use in measuring the CCA-IMT isnificantly correlated with the CCA-IMT when
now established as a method.16–19 It can be concludedmeasured by ultrasonography.10 Increased CCA-IMT
from these studies that the IMT may represent theis strongly associated with a risk of stroke11 and small
sum of the cardiovascular risk in an individual. There-changes in the CCA-IMT were also associated with
fore, the IMT is expected to be increased in those withclinically significant atherosclerosis in the peripheral
established vascular disease.
Cholesterol-lowering treatment effectively prevents
∗ Please address all correspondence to: G. Hamilton, Consultant IHD-related events and strokes20,21 and also sig-
Vascular Surgeon, Vascular Unit, University Department of Surgery,
nificantly reduces overall mortality in patients withRoyal Free Hospital NHS Trust, Pond Street, London NW3 2QG,
U.K. established IHD.22 In turn, hyperlipidaemia pre-
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lowering treatment causes CCA-IMT regression.24,25awarded the prize of the best paper presentation in the junior
vascular surgeon session. Therefore, we monitored the CCA-IMT and CFA-IMT
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Table 1. Baseline characteristics of the patients. Values are ex- Carotid and femoral artery IMT measurements and trial
pressed as mean (SD) unless otherwise stated.
design
Patient characteristics
A variety of IMT measurement protocols, based on
No. of patients 25 different ultrasound methods, have been developedAge median (range) (years) 69 (48–81)
Gender (M,F) 14,11 in order to obtain reliable and reproducible results.26
BMI (kg/m2) 26.5 (2.8) We used an automatic technique,17 that has been val-
Systolic BP (mmHg) 145 (10) idated against the conventional manual technique;Diastolic BP (mmHg) 87 (8)
No. of current smokers (%) 5 (20%) there was a significant correlation between the two
No. of ex-smokers (%) 20 (80%) methods.27 This technique has been described else-
No. of patients on aspirin (%) 18 (72%) where in detail;17,27 in brief, patients were scanned inNo. of patients on antihypertensives (%) 20 (80%)
the supine position and electrocardiographic (ECG)
BMI=body mass index. leads were placed appropriately on the chest wall for
ECG R-wave triggered measurements. A longitudinal
B-Mode image of the blood vessel was visualised using
in patients with peripheral vascular disease (PVD) and a duplex ultrasonography scanner with a 7.5 MHz
raised serum cholesterol 4 and 8 weeks after treatment linear-transducer (Scanner 350, Pie Medical System,
with atorvastatin. The aim of the study was to establish Maastricht, The Netherlands), then switched to echo
whether the IMT was significantly changed within this M-mode with a high pulse-repetition frequency and
short period. a short activation pulse. The radio frequency (RF)
signals were transferred to a computer with wall track-
ing software and the IMT was determined auto-
matically (WTS ver 2.0, Pie Medical System,Methods
Maastricht, The Netherlands).17
The IMT was measured at the posterior wall, becauseA total of 25 patients (14 men and 11 women), median
the trailing edge of the adventitia signal of the anteriorage 69 years (range: 48–81) were recruited. Their pre-
wall will obscure the media and influence the measure-treatment characteristics are shown in Table 1. The
ment of this IMT. On the other hand the far wall isstudy population consisted of patients who were re-
well visualised and likely to show the earliest ath-ferred to a university hospital vascular surgery clinic
erosclerotic changes.17 The same locations of arterieswith stable PVD and who were found to have a serum
were scanned pre-treatment as well as at 4 and 8cholesterol level [5.5 mmol/l. PVD was defined as
weeks after treatment with atorvastatin (Lipitor)stable uncomplicated intermittent claudication with
20 mg/day.an ankle/brachial pressure index <0.08.
The IMT measurements were taken 2 cm proximal
to the carotid bifurcation. The IMT was expressed as
the mean of six measurements taken at each visit;
these were blindly analysed. The same method wasExclusion criteria
used for the femoral artery measurements, which were
taken 2 cm proximal to the origin of the superficialPatients with critical leg ischaemia, significant carotid
femoral artery.artery disease (>70% stenosis) or previous carotid
surgery, diabetes mellitus, poorly controlled hyper-
tension, serum creatinine level above the upper limit of
the reference range (120 mol/l) and patients receiving
Ethics, data collection and statistical analysislipid-lowering treatment were excluded.
The Ethics Committee of the Royal Free Hospital NHS
Trust approved the study and written consent was
obtained from each patient. The data was blindlyBlood samples and measurements
analysed by giving random numbers to each measure-
ment of IMT and each blood sample. Paired t-testsA fasting (12 h) venous sample was obtained to assess:
(1) Lipid profile, (2) haematological and biochemical were used to check if the changes in IMT (pre-treatment
vs 4 weeks and pre-treatment vs 8 weeks) and lipidprofile, (3) plasma fibrinogen and factor XII levels (as
indices of the coagulation system), and (4) renal and profile (pre-treatment vs 8 weeks) were significant.
The multivariate ANOVA test was used to assess theliver function tests.
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Table 2. Changes in serum creatinine, serum urea, serum urate, plasma fibrinogen and plasma factor XII after 8 weeks of treatment
with 20 mg/day of atorvastatin. The results are expressed as median and range.
Test Pre-treatment 8 weeks p value
Serum creatinine (mol/l) All patients (n=25) 87 (67–114) 84 (64–112) 0.007
Patients with the highest 12 creatinine 98 (89–114) 91 (83–112) 0.008
values∗
Patients with the lowest 13 creatinine 77 (67–84) 77 (64–85) NS
values∗
Serum urate (mmol/l) All patients (n=25) 0.33 (0.17–0.43) 0.32 (0.19–0.40) NS
Patients with the highest 12 creatinine 0.33 (0.24–0.43) 0.32 (0.22–0.40) 0.04
values∗
Patients with the lowest 13 creatinine 0.29 (0.17–0.40) 0.30 (0.19–0.35) NS
values∗
Urea (mmol/l) 5.7 (1.9–9.6) 5.4 (1.8–9.1) NS
Fibrinogen (mg/l) 323 (216–565) 304 (194–494) NS
Factor XII (ng/ml) 1.7 (0.7–2.8) 1.2 (0.7–4.2) NS
NS=not significant, ∗ pre-treatment.
Table 3. Changes in the lipid profile after 8 weeks treatment withtrend of changes in IMT over the whole study period
atorvastatin 20 mg/day.(i.e. 8 weeks). The significance of the changes in serum
Pre-treatment 8 weeks p valuecreatinine levels before and after treatment for 8 weeks
was assessed using a paired Wilcoxon test. A p value
Total cholesterol 6.0 (0.3) 4.3 (0.8) 0.0004of <0.05 was considered statistically significant. Cor- (mmol/l)
LDL (mmol/l) 3.7 (0.2) 2.2 (0.5) 0.0001relation was assessed by deriving the Pearson’s co-
HDL (mmol/l) 1.8 (0.6) 2.0 (0.5) NSefficient. The primary end point was to measure the
TG (mmol/l) 1.3 (0.4) 0.8 (0.3) 0.05changes in carotid and femoral IMT after 8 weeks of
LDL=low density lipoprotein cholesterol, HDL=high density lipo-treatment. Secondary end points were the changes in
protein cholesterol, TG=triglycerides.the other variables measured in the blood.
lipoprotein cholesterol (LDL) (p=0.0001). There wasResults
no significant change in the HDL level. The tri-
glyceride levels decreased significantly (p=0.05).Biochemical results
After 8 weeks treatment all the patients had a LDL
level <3.0 mmol/l, the UK guideline value for patientsThere was no statistical difference in the haemato-
with vascular disease.28logical profile between visits at 0 and 8 weeks (results
not shown). There was a significant (p=0.007) decrease
in serum creatinine values. The patients were divided
into two halves, one with the highest serum creatinine
Changes in carotid and femoral IMTlevels (n=12) and the other (n=13) with the lowest
serum creatinine levels. The decrease in serum cre-
The ANOVA test for the trend was significant (p=atinine was only significant (p=0.008) in the “higher
0.024) for the CCA-IMT and for the CFA-IMT (p=creatinine” group. Similarly, there was fall in the serum
0.0003). The changes in CCA-IMT and CFA-IMT wereuric acid value in the group with a higher creatinine.
not significant when the pre-treatment and 4-weekThere were no significant changes in liver function
values were compared. However, they were significanttests, creatine kinase, fibrinogen, urea and factor XII
(p=0.01 CCA-IMT; p=0.005 CFA-IMT) when the pre-levels (Table 2).
treatment and 8-week values were compared (Table
4). There was no significant correlation between the
carotid and the femoral IMT values pre-treatment or
at the end of the 8 weeks treatment. A decrease of theChanges in the lipid profile
CCA-IMT by >0.1 mm was noted in 10 patients (40%)
after 4 weeks and in 18 patients (72%) after 8 weeks ofTable 3 summarised the lipid profile data. After 8
weeks of treatment there was a significant reduction treatment. For the CFA-IMT the corresponding figures
were 8 (32%) and 19 (76%) patients, respectively (Fig.in total cholesterol (p=0.0004) and in low density
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Table 4. Right common carotid artery (CCA) and right common arteries may not respond at the same rate to lipid
femoral artery (CFA) IMT before and after treatment with 20 mg/
lowering. Indeed a greater decrease in the CFA-IMTday atorvastatin.
compared with the CCA-IMT was reported after statin
Arteries Pre-treatment 4WP 8WP ∗p value treatment (mainly with pravastatin or simvastatin) for
a period of 1 year.33 An alternative explanation isCCA-IMT 0.79 (0.21) 0.75 (0.22) 0.64 (0.15) 0.024
CFA-IMT 0.83 (0.13) 0.80 (0.09) 0.69 (0.14) 0.0003 that the CFA-IMT is a more relevant measurement in
patients with PVD. Others have proposed that initial∗ANOVA test for the trend over the 8 week treatment period.
lipid-lowering therapy is associated with a greater4WP, 4 weeks post-treatment; 8WP, 8 weeks post-treatment. The
IMT (mm) is expressed as mean±SD. improvement in the CFA-IMT and CCA-IMT than
when this form of treatment was intensified in patients
1). There was no correlation between the changes in already taking statins.33 The baseline lipid levels were
the lipid levels and the IMT. similar in both these treatment groups and the CFA-
IMT and CCA-IMT were assessed after treatment with
statin for 1 year.33
It is important to consider that rapid changes in
Side effects endothelial function (within as little as 1 month) have
been reported.25,31,32 Furthermore, in the Myocardial
There were no side effects, vascular events or dropouts Ischaemia Reduction with Aggressive Cholesterol
during this 8-week study. Lowering (MIRACL)34 study there was an unexplained
significant (p=0.045) and marked (50%) reduction in
strokes in patients with acute coronary syndrome who
were treated for 16 weeks with atorvastatin (80 mg/
Discussion day). MIRACL was a placebo controlled, double blind,
randomised study and it included >3000 patients.34
Achieving U.K. guideline values for LDL (<3.0 mmol/ Clearly there is a need to further investigate the
l) within 8 weeks using atorvastatin (20 mg/day) in rapid changes in the vasculature that follow lipidpatients with PVD was associated with a significant
lowering treatment. This (unfortunately) should in-decrease in the CCA-IMT and CFA-IMT. These findings
clude animal-based studies so as to allow for theconfirm those of our preliminary study where we only
extensive histological and functional investigation ofassessed the CCA-IMT under similar circumstances.25
several arteries.We attributed this rapid improvement to anti-in-
A decrease in carotid artery IMT with atorvastatinflammatory changes25 because it is unlikely that in this
has been previously documented but the time scaleshort time span there could be a significant reduction
was of the order of 12–24 months.35,36 The patientsin lipid deposits in the intima and media. Our con-
had familial hypercholesterolaemia and the dose ofclusion is based on the findings of an experimental
atorvastatin was considerably higher (80 mg/day)model of carotid injury. In this model, a decrease in
compared to what we used in the present studyintimal thickening, smooth muscle cell proliferation
(20 mg/day).and infiltration by macrophages was noted after the
The significant (p=0.007) fall in serum creatinineadministration of a statin for 2 weeks.29 Furthermore,
levels was relatively unexpected. However, we as-there is evidence that atorvastatin can significantly
sessed that variable on the basis of anecdotal ob-reduce the circulating levels of C-reactive protein in
servations in patients with PVD after correcting theirpatients with combined hyperlipidaemia after treat-
dyslipidaemia. We also previously reported similarment for 6 weeks.30 Improvement in endothelial func-
changes in serum uric acid in dyslipidaemic patientstion is also reported within 1 month of lipid lowering
treated with atorvastatin.37 We interpret these findingstreatment.31,32
as indicating an increase in renal perfusion followingObserving a trend as early as 4 weeks after com-
lipid-lowering treatment. This improvement was mostmencing atorvastatin supports the rapidity of the effect
evident (p=0.008) in the 50% of our study populationof lipid lowering treatment on the IMT. Although
with the highest pre-treatment serum creatinine val-the 4-week IMT measurements were not significantly
ues. In this context, it is relevant that others havedecreased when directly compared with pre-treatment
proposed that the improvement in microalbuminuriavalues, they were included as part of the ANOVA
(and blood pressure) after treatment with statins isanalysis. This latter analysis was significant for both
related to an increased production of nitric oxide (NO)the CCA-IMT (p=0.024) and CFA-IMT (p=0.0003).
This difference in significance suggests that these in the kidney.38 NO is a vasodilator and may well
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Fig. 1. Distribution of the common carotid (a) and common femoral (b) IMTs for the three measurements (baseline and after 4 and 8
weeks treatment). The horizontal line represents the mean value. For statistical analysis please see Table 4 and text.
improve renal blood flow.38 It is also of interest that in larger placebo-controlled studies with a randomised
design. These studies should also include a moremicroalbuminuria is associated with an increased ca-
rotid IMT.39 A further possible effect of statin treatment detailed assessment of renal function. However, these
changes may be restricted to a specific patient popu-is a reduction or stabilisation of plaque in the renal
arteries. Localised renal atherosclerosis is probably lation.
Our findings have several limitations. Our studypresent to a variable degree in patients with PVD.40
The hypothesis that improved renal blood flow was was not placebo controlled or randomised and the
number of patients was small (n=25). We selected aresponsible for our observations requires confirmation
Eur J Vasc Endovasc Surg Vol 23, April 2002
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